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ABSTRACT
In glioblastoma multiforme (GBM), cancer stem cells (CSCs) are thought to be 
responsible for gliomagenesis, resistance to treatment and recurrence. Unfortunately, 
the prognosis for GBM remains poor and recurrence frequently occurs in the peritumoral 
tissue within 2 cm from the tumor edge. In this area, a population of CSCs has been 
demonstrated which may recapitulate the tumor after surgical resection. In the present 
study, we aimed to characterize CSCs derived from both peritumoral tissue (PCSCs) and 
GBM (GCSCs) in order to deepen their significance in GBM development and progression. 
The stemness of PCSC/GCSC pairs obtained from four human GBM surgical specimens 
was investigated by comparing the expression of specific stem cell markers such as 
Nestin, Musashi-1 and SOX2. In addition, the growth rate, the ultrastructural features 
and the expression of other molecules such as c-Met, pMet and MAP kinases, involved in 
cell migration/invasion, maintenance of tumor stemness and/or resistance to treatments 
were evaluated. Since it has been recently demonstrated the involvement of the long non-
coding RNAs (lncRNAs) in the progression of gliomas, the expression of H19 lncRNA, as 
well as of one of its two mature products miR-675-5p was evaluated in neurospheres. Our 
results show significant differences between GCSCs and PCSCs in terms of proliferation, 
ultrastructural peculiarities and, at a lower extent, stemness profile. These differences 
might be important in view of their potential role as a therapeutic target.
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INTRODUCTION
It is currently believed that many solid tumors, 
including glioblastoma multiforme (GBM), develop from 
a small subset of cells with stem cell properties, termed 
“cancer stem cells” (CSCs) [1]. These cells reside in an 
aberrant niche that contains a variety of different stromal 
cells such as mesenchymal and immune cells, and presents 
a complex architecture with abnormal extracellular matrix 
components and an atypical vascular network [2]. Likewise 
normal stem cells, GBM CSCs show self-renewal, high 
proliferative potential, as well as the ability to differentiate 
into various tumor cell types [3]. From a clinical point 
of view, one of the main concerns with CSCs is their 
resistance to common chemo-radiotherapy, that can favor 
tumor recurrence [4, 5].
Although the administration of temozolomide has 
significantly improved patients’ overall survival [6], 
their outcome remains very poor with a life expectancy 
ranging from 14.6 to 16.7 months [7]. Due to the central 
role of vascularization in GBM progression, additional 
anti-angiogenic targeted therapies have been attempted 
without resulting in any significant improvement [8, 9]. In 
the absence of effective therapies, about 90% of patients 
show a high recurrence rate within 2 cm from tumor 
edge [10, 11], suggesting that the proximity to the tumor 
microenvironment most likely causes alterations in the 
peritumoral area and local relapse [12–14]. Therefore, 
the molecular and functional characterization of GBM 
neighboring tissue has raised great interest as a potential 
therapeutic target, although, data are still sparse compared 
to the amount of reports concerning tumor tissue [15]. In 
our previous studies, the expression of phosphorylated 
extracellular signal-regulated kinases 1/2 (pERK1/2), 
phosphorylated c-Jun NH2-terminal kinases (pJNK), stem 
cell markers such as Nestin, CD133, GD3 ganglioside 
and NG2 proteoglycan, as well as angiogenesis-related 
factors (CD105, VEGF, VEGFR1/2, HIF-1α and HIF-2α), 
has been demonstrated in both GBM and peritumoral 
tissue [16–21]. Interestingly, in the latter area, the above 
markers were expressed not only in cancer cells or reactive 
astrocytes, but also in apparently normal cells, even in 
the absence of frankly neoplastic cells, which suggests 
ongoing malignant transformation events.
The presence of elements with stem cell features 
in such an altered microenvironment might support 
their identity as CSCs, the most suitable candidates for 
the recurrence. Putative CSCs isolated from different 
regions of the same GBM or from the tumor mass and 
its neighboring tissues have been already reported to bear 
different characteristics in terms of growth properties, 
clonogenic potential, genetic abnormalities and in vivo 
tumorigenicity [22–24, 19]. In this framework, the present 
study aims to improve the characterization of CSCs 
obtained from GBM peritumoral tissue macroscopically 
devoid of neoplastic cells (PCSCs), by comparing their 
molecular profile and structural features to those derived 
from the tumor mass (GCSCs) [19]. In particular, the 
expression of stem cell markers (Nestin, Musashi-1 and 
SOX2), c-Met and its activated form pMet, pERK1/2, 
pJNK, H19 lncRNA and its encoded miR-675-5p, as well 
as the growth and ultrastructural characteristics of both 
GCSCs and PCSCs, were investigated. Nestin is a protein 
belonging to class VI of intermediate filaments, expressed 
during nervous system development and in adult stem and 
progenitor cells [25]. In GBM Nestin appears related to 
tumor cell dedifferentiation, invasiveness and malignancy 
[26–28]. Nestin knockdown in human GBM cell lines 
suppresses proliferation, migration and invasion, and 
increases F-actin expression and cell adhesion to the 
extracellular matrix [29]. Musashi-1 is a highly conserved 
RNA-binding protein with an essential role in stem cell 
phenotype maintenance and nervous system development. 
The expression of Musashi-1 is restricted to embryonic 
development and adult stem and progenitor cells but its 
overexpression occurs in tumors where it induces cell 
proliferation, differentiation arrest, apoptosis inhibition 
and allows self-renewal and pluripotency maintenance 
[30]. Together with Nestin and Musashi-1, SOX2, 
a nuclear transcription factor belonging to the SOX 
family, represents a master regulator of pluripotency and 
controls a variety of genes involved in the maintenance 
of the undifferentiated state during embryogenesis. In 
adults, SOX2 is re-expressed in cancer cells, particularly 
in the early stages of tumor development, suggesting 
its involvement in tumor-initiating events [31]. The 
maintenance of tumor stemness in GBM CSCs has been 
also recently attributed to the activation of c-Met, the 
tyrosine kinase receptor of the hepatocyte growth factor/
scatter factor (HGF/SF), which also seems to mediate the 
acquisition of GBM CSCs radiotherapy resistance [32]. 
Moreover, the activation of extracellular signal-regulated 
kinases (ERK1/2) signaling can drive the expansion 
of CSC population and/or its innate radio-resistance in 
different tumors [33, 34]. Mitogen-activated protein 
kinases (MAPK)-ERK1/2, as well as JNK pathways, are 
essential for the stem cell-like properties of GBM CSCs 
[35, 36]. Moreover, Sunayama et al. reported that the 
concurrent inhibition of PI3K/AKT/mTOR and MAPK/
ERK pathways effectively promotes GCSC differentiation 
and thereby suppresses their tumorigenicity [37]. Recent 
findings, suggesting the key role of endogenous cellular 
long noncoding RNAs (lncRNAs) in cancer progression, 
encouraged us to focus on H19 lncRNA, that has 
been found highly expressed in placenta, embryonic/
fetal tissues and in several tumors including GBM 
[38, 39]. One of the two mature forms of miRNA 
generated from H19 lncRNA is miR-675-5p. H19 lncRNA 
and its derivate miR-675-5p positively correlate with 
glioma grade and the H19/miR-675 signaling axis has 
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been recently reported to promote glioma cell invasion 
[40]. In our study, a comparative analysis of the expression 
of all the above-described molecules as well as of cell 
growth and structural features was performed on GCSC/
PCSC pairs derived from four patients affected by primary 
GBM. Even though a high heterogeneity in the expression 
of stemness markers was found between PCSC/GCSC 
pairs, the results obtained suggest that PCSCs have a 
less malignant phenotype with respect to GCSCs, lower 
proliferative activity and some ultrastructural features 
related to a lower invasiveness. This study provides new 
insights into the biology of PCSCs, which may help in 
defining their potential role in GBM progression and 
improve patients’ treatment.
RESULTS
Morphology and proliferative activity of GCSCs 
and PCSCs
The morphology of neurospheres was observed 
by a phase-contrast microscope. GCSC and PCSC 
neurospheres displayed a bright surface and some of them 
showed a well-defined spherical contour, whereas others 
showed an irregular surface. In addition, while GCSCs 
obtained from all the four patients appeared, as expected, 
as free-floating neurospheres, PCSCs from patient #3 and 
#4 were semi-adherent (Figure 1A), indicating a certain 
heterogeneity among pairs. The proliferative capability 
of both cell populations was investigated at 2, 4 and 
7 days in culture. The results of this analysis indicated a 
higher proliferation rate of GCSCs compared to PCSCs 
(p < 0.001) (Figure 1B).
Stemness markers, c-Met, ERK1/2, JNK, H19 
lncRNA and miR675-5p expression
Nestin expression
In order to assess the stemness profile of GCSCs and 
PCSCs, we evaluated the expression of the intermediate 
filament protein Nestin. Our analysis revealed that Nestin 
coding gene (Nes) was expressed at a different extent 
in both GCSCs and PCSCs (Figure 2). In particular, in 
patient #3, the Nes level was lower in PCSCs than in 
GCSCs (p < 0.001), whereas in patient #4 a higher Nes 
expression was observed in PCSCs (p < 0.001). No 
significant difference in Nestin mRNA level was found 
between PCSCs and GCSCs of patient #1 and #2. With 
respect to the heterogeneity seen in Nes gene expression, 
Western blot analysis demonstrated lower levels of Nestin 
protein in all PCSCs compared to GCSCs (Figure 3A; 
p < 0.05, p < 0.01). Immunohistochemical analysis showed 
a diffuse Nestin staining in the cytoplasm of both cell types 
(Figure 3B).
Musashi-1 expression
Due to its role in the maintenance of the stem-cell 
state, Musashi-1 gene (Msi1) and protein expression 
were analyzed. Similarly to Nes, Msi1, although detected 
in all pairs of CSCs, showed a heterogeneous pattern 
of expression among the different PCSC/GCSC pairs 
(Figure 2), while Musashi-1 protein levels resulted lower 
in all PCSCs compared to GCSCs (Figure 3C; p < 0.05). 
As shown in Figure 3D, immunoreactivity of Musashi-1 
protein was detected in both cytoplasmic and nuclear 
compartment of both GCSCs and PCSCs.
SOX2 expression
The expression of the stem cell marker SOX2 
was evaluated at the mRNA and protein level. Sox2 
gene expression did not display a definite trend among 
the different GCSC/PCSC pairs (Figure 2). Western 
blot analysis demonstrated a comparable level of SOX2 
protein in all samples of GCSCs and PCSCs, with the 
only exception of patient #2 where it was higher in 
PCSCs (Figure 3E; p < 0.01). SOX2 immunolabeling was 
restricted into the nucleus in both cell types, indicating the 
activated status of the protein (Figure 3F).
c-Met expression
The analysis of the receptor tyrosine kinase c-Met 
expression by qPCR demonstrated that c-Met gene 
level in PCSCs of patients #1 and #2 was higher than in 
GCSCs (Figure 2, p < 0.001). In patients #3 and #4 c-Met 
expression was lower in PCSCs (Figure 2; p < 0.001). 
As for c-Met protein expression, similarly to what was 
described for Nestin and Musashi-1, it was significantly 
lower in PCSCs compared to GCSCs (Figure 3G; 
p < 0.05 and p < 0.005). However, none of the four CSC 
pairs analyzed showed detectable level of the activated 
form of c-Met (pMet; data not shown). The c-Met 
expression was widely detected in both PCSC and GCSC 
populations (Figure 3H) and the immunoreactivity was 
mainly localized in both the cytoplasm and the nucleus.
ERK1/2 and JNK expression
As regards ERK1/2 and JNK expression, our data 
indicated lower levels of MAPK3 gene (coding for ERK1 
protein) in PCSCs of patients #1 and #2 (p < 0.01 and 
p < 0.05, respectively), while no significant difference was 
observed between GCSCs and PCSCs of patients #3 and 
#4 (Figure 2). No significant variations were detected in 
the transcript levels of MAPK1 (coding for ERK2 protein) 
and MAPK8 (coding for JNK protein), except for one 
patient (#2), among GCSC and PCSC pairs (Figure 2).
As for the expression of the phosphorylated (p) form 
of ERK1/2 and JNK, Western blot analysis demonstrated 
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that PCSCs displayed levels of pERK1/2 higher than 
GCSCs in three out of four neurosphere pairs (Figure 3I). 
On the contrary, as regards pJNK, the protein level was 
consistent with the expression of most of the stem cell 
markers analyzed, being lower in PCSCs (Figure 3K). 
The apparent discrepancy between pERK1/2 and pJNK 
profile expression might be due to multiple mechanisms 
of MAPK activation [41]. Immunocytochemical analysis 
showed the presence of both pERK1/2 and pJNK in the 
cytoplasm as well as in some of the nuclei of GCSCs and 
PCSCs (Figure 3J, 3L).
H19 lncRNA and miR675-5p expression
As for H19 lncRNA, no specific trend of expression 
was apparent in the GCSC/PCSC pairs (Figure 4). Indeed, 
no significant differences were observed in H19 lncRNA 
levels between PCSCs and GCSCs from patients #1–3, 
Figure 1: Morphological and proliferation analysis of GCSC/PCSC pairs. (A) GCSCs derived from all the four patients, as 
well as PCSCs obtained from patients #1 and #2, grew as floating neurospheres. PCSCs corresponding to patients #3 and #4 grew as semi-
adherent cells. Original magnification, ×400. (B) In each GCSC/PCSC pair (#1–4) analyzed, GCSCs (rumble) show a higher proliferation 
rate if compared to PCSCs (square). Values represent the mean ± SD of three independent experiments. Data were analyzed by Student 
t test, **p < 0.001 vs GCSCs. 
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while it was clearly enriched in GCSCs obtained from 
patient #4. In addition, we measured the expression levels 
of miR-675-5p, the prevalent mature form of miR-675 
(www.mirbase.org). MiR-675-5p expression in GCSC/
PCSC pairs revealed the same trend as of H19 lncRNA 
in the neurosphere pairs derived from patients #1, #2 and 
#4, while in the GCSC/PCSC pair of patient #3 it did not 
mirror that of H19 lncRNA, being lower in PCSCs.
Ultrastructural features 
TEM ultrastructural analysis of GCSCs (Figure 5) 
and PCSCs (Figure 6) was performed on neurospheres 
derived from biopsies of four different GBM patients. 
All examined cell cultures contained a phenotypically 
heterogeneous population and cells were generally 
arranged in rounded formations.
PCSCs and GCSCs shared several characteristics, 
such as irregular nuclei, mainly constituted by euchromatin 
with marginated heterochromatin (Figures 5A, 5B 
and 6A, 6B, 6F) and prominent nucleoli (Figures 5A, 
5B and 6F). Rough endoplasmic reticulum, vesicles, 
intermediate filaments (Figures 5C, 5D and 6A–6C, 6E–
6H) and mitochondria (Figures 5A, 5C and 6A–6C, 6E) 
were also visible in the cytoplasm. In addition, the plasma 
membranes of both PCSCs and GCSCs showed abundant 
microvilli (Figures 5A and 6A, 6D and 6E).
Lipid droplets as well as primary and secondary 
lysosomes were observed in GCSCs (Figure 5A, 5B, 5D). 
In particular, primary lysosomes are smaller and 
homogeneously electron dense while the secondary 
lysosomes are bigger and irregularly electron-dense 
because they contain digested material. The GCSC plasma 
membranes showed loose cell-cell contacts (Figure 5B, 5D); 
organized desmosomes or junctional complexes were not 
detected, while they were visible in PCSCs (Figure 6D). 
In addition, PCSCs were particularly rich in glycogen. 
Glycogen, stored free in the cytoplasm, was visible as 
electron-dense particles about the size of ribosomes 
(Figure 6C). Intermediate filaments were apparently more 
abundant in these latter neurospheres, if compared to 
GCSCs (Figure 6). In particular, intermediate filaments 
were variously arranged and located in the cytoplasm 
(Figure 6A, 6B, 6E, 6G and 6H) and in the perinuclear 
Figure 2: Nes, Msi1, Sox2, c-Met, MAPK3, MAPK1 and MAPK8 gene expression in GCSC/PCSC pairs. The expression level 
of the indicated genes was evaluated by qPCR in GCSCs and PCSCs. The relative RNA quantity was normalized to GAPDH endogenous 
control. Nes (gene coding for Nestin protein), Msi1 (gene coding for Musashi-1 protein), Sox2 (gene coding for SOX2 protein), c-Met (gene 
coding for c-Met protein), MAPK3 (gene coding for ERK1 protein), MAPK1 (gene coding for ERK2 protein) and MAPK8 (gene coding 
for JNK protein). Bar graph show mean ± SE from three independent experiments. Data were analyzed by t-test pooled variance, °p < 0.05, 
°°p < 0.01 and **p < 0.001 vs GCSCs. 
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Figure 3: Nestin, Musashi-1, SOX2, c-Met, pERK1/2 and pJNK protein expression in GCSC/PCSC pairs. Nestin (A), 
Musashi-1 (C), SOX2 (E), c-Met (G), pERK1/2 (I) and pJNK (K) protein expression was evaluated by Western blot analysis. Representative 
blots from three separate experiments yielding similar results are shown. The intensity of bands was quantified by densitometric analysis 
and normalized to those of β-actin (used as loading control). The values shown represent the mean ± SD of three independent experiments. 
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Data were analyzed by Student t-test, °p < 0.05, °°p < 0.01, *p < 0.005 and **p < 0.001 vs GCSCs. Immunocytochemical analysis of 
Nestin (B), Musashi-1 (D) and SOX2 (F), c-Met (H), pERK1/2 (J) and pJNK (L) performed on GCSC and PCSC frozen sections 
(10 μm). All the investigated markers were expressed in both cell populations. Nestin immunoreactivity was found at the level of cell 
cytoplasm (B). Musashi-1 specific staining was seen in both the cytoplasm and the nucleus (D). SOX2 staining was mainly detected in 
the nucleus (F). c-Met (H), pERK1/2 (J) and pJNK (L) immunoreactivity was present at the level of both the cytoplasm and the nucleus. 
Original magnification, ×630. Details of immuno-positive and -negative cells are shown at higher magnification in the bottom left insets 
(B, D, F, H, J, L). 
Figure 4: H19 lncRNA and miR-675-5p expression in GCSC/PCSC pairs. The expression level of H19 lncRNA and miR-
675-5p was evaluated by qPCR in GCSCs and PCSCs. All values were expressed as compared to those found in human astrocytes, where 
H19 expression was set = 1. Expression levels were normalized against U6 snRNA and TBP mRNA as controls for miR-675-5p or H19 
lncRNA, respectively. The values shown represent the mean ± SD of two independent experiments. Data were analyzed by Student t-test; 
°p < 0.05 vs GCSCs.
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region (Figure 6F). In addition, PCSCs showed long 
processes supported by abundant microtubules (Figure 6I) 
and intermediate filaments. These processes established loose 
cell-cell contacts with neighbouring cells (Figure 6G–6I).
DISCUSSION
It is now widely accepted that GBM, as it occurs in 
other tumors, is initiated and maintained by CSCs, referred 
to as a subset of cells with stem-like properties that 
display an unlimited proliferative capacity and ability to 
differentiate into the different cell types that compose the 
tumor mass. Due to their high resistance to conventional 
treatments [4, 5, 42] and despite the aggressive therapy 
commonly administered to patients, the presence of this 
cell population can account for the high frequency of 
recurrence seen in GBM-affected patients. To this regard, 
it is likely that CSCs are also present in the peritumoral 
tissue where they may function as a reservoir of cancer 
initiating cells after surgical resection. Previous reports 
have demonstrated that GBM induces alterations in the 
peritumoral tissue by producing soluble factors that 
contribute to the establishment of an aberrant niche that 
allows CSCs to survive and resist to common therapies 
[12–14]. The present study aimed to expand our previous 
findings [16–21] on the role of the peritumoral tissue 
during GBM progression by focusing on the molecular 
and structural characterization of CSCs residing in this 
area. Therefore, we investigated and compared in GCSCs 
and PCSCs the expression of stem cell markers as well 
as molecules involved in the maintenance of tumor 
stemness and/or resistance to treatments, the proliferative 
activity and the ultrastructural features. In agreement with 
findings by other authors [22–24] and with our previous 
observations [19], the results of this study support the 
existence of two different malignant populations with stem 
cell-like characteristics in GBM and in the neighboring 
tissue, respectively.
Here we report that both GCSCs and PCSCs derived 
from four patients express transcripts of Nestin, Musashi-1, 
Figure 5: Ultrastructural analysis of GCSCs. GCSCs showed irregular nuclei (N) mainly formed by euchromatin with marginated 
heterochromatin and prominent nucleoli (n) (A, B). Rough endoplasmic reticulum (RER), mitochondria (m), vesicles (v) and intermediate 
filaments (IF) were visible in the cytoplasm (C, D). Lipid droplets (L), primary and secondary lysosomes (ly and ly*, respectively) were 
observed (A, B and D). Plasma membranes showed microvilli (mv) (A) and loose cell-cell contacts (square in B and at higher magnification 
in D). Scale bars = 2 µm.
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SOX2, c-Met, MAPK1/3 and JNK. Nevertheless, it 
was not possible to draw a definite trend, due to the 
high heterogeneity in gene transcript levels shown by 
GCSCs and PCSCs isolated from different patients. 
This might be explained by the existence of various 
CSC subpopulations endowed with a different stemness/
malignancy signature within the neurospheres derived 
from GBM and peritumoral tissue. This hypothesis may 
also support our findings on protein expression, which 
does not always match the mRNA levels. This is not a 
surprising event since various mechanisms may contribute 
to the protein synthesis rate and half-life [43]. However, 
the higher protein levels of both Nestin and Musashi-1, 
expressed by GCSCs, indicate a less differentiated as 
well as a more aggressive status of these CSCs compared 
to PCSCs. Concerning SOX2, which is thought to play 
a key role in the maintenance of GBM stem-like cell 
properties, we found an overall comparable protein level 
in GCSCs and PCSCs. This may be due to the existence of 
a specific CSC hierarchy which determines the timing of 
expression of stemness markers during stem cell neoplastic 
transformation [44]. Then, SOX2 may be expressed by 
CSCs in the early phases of their malignant transformation 
and its level might remain unchanged in GCSCs. 
Consistent with this hypothesis, it has been previously 
demonstrated that SOX2 mRNA expression was greater in 
lower grade gliomas [45].
Since the activation of c-Met in GBM has been 
demonstrated to be involved in the establishment of 
radiotherapy resistance as well as in the expansion 
and maintenance of stemness features of the CSC pool 
[32, 46], the higher levels of c-Met found in GBM CSCs 
were not surprising [47, 48]. As previously reported by 
others, we did not detect the expression of the activated 
form of c-Met (pMet) under basal growth conditions [49]. 
However, we found c-Met immunostaining into the nuclei 
that may indicate the presence of the C-fragment, produced 
by a proteolytic cleavage of c-Met, which is independent 
from the ligand activation. The nuclear C-fragment 
seems to act as a transcription factor of genes involved in 
Figure 6: Ultrastructural analysis of PCSCs. PCSCs showed irregular nuclei (N) (A, B and F) and sometimes multiple nuclei with 
evident nucleoli (n) (F). Mitochondria (m) were visible (A–C, E). Cells were particularly rich in intermediate filaments (IF) located in 
the cytoplasm and in the perinuclear region (A, B, E–H). Microvilli (mv) were present on the cellular membrane (A, D and E). Abundant 
glycogen (g) stored free in the cytoplasm (C) was noted. Fully organized desmosomes (d) were also visible (D). Loose cell-cell contacts 
were established by cellular processes rich in IF (square in G and at higher magnification in H) and microtubules (mt) (I). Scale bars = 2 μm. 
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migration and invasiveness [50]. However, the expression 
of c-Met in PCSCs confirms the malignant nature of 
the stem cells residing in the peritumoral area and may 
contribute to explain their radio-resistance. In addition, the 
expression of pERK1/2 and pJNK in GCSCs and mainly in 
PCSCs has particular relevance since these molecules are 
known to be altered in pathological conditions, in which 
they increase proliferation and promote migration and 
invasion. Indeed, Nakada and coworkers showed that the 
activation of ERK1/2 correlates with an overexpression of 
integrin α3 that may contribute to the invasive nature of 
CSCs in GBM [51]. Moreover, it has been reported that 
treatment with retinoic acid triggers differentiation and, in 
turn, reduces proliferation and self-renewal in GBM CSCs 
in an ERK1/2-dependent manner [52]. The JNK function 
in GBM biology is complex and needs to be fully defined. 
In agreement with our results, high JNK levels have been 
described in self-renewing GBM CSCs and its knockdown 
or pharmacological inhibition determined the reduction 
of sphere formation, clonogenicity and stem cell marker 
expression [53, 54]. These events indicate that the JNK 
signaling pathway represents an important mechanism in 
the maintenance of the stemness features of GBM CSCs. 
As for the above markers, the detection of activated JNK 
in PCSCs confirms their tumor stem cell identity. A role in 
GBM stem-like cell biology has also been recently reported 
for the H19 lncRNA [55]. The authors demonstrated that 
overexpression of H19 lncRNA in stem-like cells derived 
from two human GBM cell lines enhances their ability to 
form neurospheres, thus promoting their self-renewal, a 
hallmark of stem-like cells in GBM. In agreement with 
data indicating that miR-675-5p contributes to glioma cell 
invasion and positively correlates with glioma grade [40], 
we found a higher expression of the miR-675-5p in GCSCs 
of two out of four neurosphere pairs.
To the best of our knowledge, this is the first time 
that a detailed ultrastructural analysis of CSCs derived 
from peritumoral tissue has been performed and compared 
to that carried out on CSCs isolated from GBM. Here, 
we show that the two types of neurospheres share some 
features that include evident irregular nuclei, with 
prominent nucleoli indicating their malignancy, and well 
represented mitochondria, rough endoplasmic reticulum, 
vesicles and microtubules. Nevertheless, unlike PCSCs, 
which display fully organized desmosomes and junctional 
complexes, GCSCs were devoid of cell junctions and 
were characterized by loose cell-cell contacts, as also 
demonstrated by other authors [56]. These observations 
clearly indicate that GCSCs, in contrast to PCSCs, have an 
enhanced capability to migrate and invade the neighboring 
tissues. Noteworthy, microvilli occurrence on the surface 
of GCSCs and PCSCs may be related to an augmented 
resistance of these cells towards cytotoxic lymphocytes, in 
agreement with previous findings [57].
We previously demonstrated that PCSCs express 
a lower level of NG2 and Ki67 and induced, in 
immunocompromised mice, intracranial tumors which 
were less vascularized if compared with those induced 
by GCSCs and with a proliferative potential similar to 
grade III gliomas [19]. The present study demonstrate that 
CSCs residing in the peritumoral tissue show different 
behavior with respect to those present in GBM. In fact, the 
comparison between GCSCs and PCSCs has highlighted 
differences in term of proliferative potential, ultrastructure 
and expression of stem cell markers, c-Met, MAPK, H19 
lncRNA and miR-675-5p, confirming that PCSCs are less 
aggressive. All the emerged features, taken as a whole, 
provide new insights into the cellular and molecular 
properties of PCSCs, that may be helpful in view of 
finding a suitable treatment and should lead to a deeper 
knowledge of GBM biology and progression.
MATERIALS AND METHODS
Neurosurgical procedure for tumor debulking.
Tumor debulking was performed in four patients 
affected by primary supratentorial GBM who did not 
receive any therapy before surgery. A very careful 
neurosurgical procedure using simultaneously two 
different computerized navigational systems was applied: 
the SteathStation® Navigational System (Medtronic, USA) 
and the MyLabXGV70® equipped with Virtual Navigator® 
(Esaote, Italy), which combine pre-surgery MR images of 
the patient with real-time ultrasound scan images acquired 
during surgery. The procedure allows for the identification 
of the necrotic areas of the tumors, non-necrotic core areas 
and peritumoral areas, which were sampled out separately. 
The two latter areas used in our experiments. The method 
is rather effective and we have previously reported data 
obtained using this technique that showed the presence of 
CSC subtypes in human GBM [19, 22, 58]. The protocol 
was approved by the Ethics Committee of the “Università 
Cattolica del Sacro Cuore”, Rome, Italy (Prot. A/205/2011) 
and all patients gave their informed consent prior to surgery.
Primary cultures and culture propagation
From each of the four patients, paired tissue 
specimens were obtained from the tumor without necrotic 
areas (GBM) and from the white matter at a distance ≤1 cm 
from the macroscopic tumor border, where neoplastic-
appearing cells were not observed (peritumoral tissue). 
As previously reported, the two areas were sampled 
separately, analyzed by an expert pathologist according 
to the World Health Organization guidelines and used in 
our experiments. Tissues (fresh surgical specimens) were 
dissected out, cut with scissors into 1 mm3 sections, then 
incubated and digested in a solution containing papain 
(24.5 U/mg; Worthington Biochemical Corp, Lakewood, 
NJ, USA) under continuous oxygenation for 45 min at 
37° C [58, 59].
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Primary cultures were then collected by 
centrifugation and plated in serum-free NeuroCult® NS-A 
Basal Medium with NeuroCult® NS-A Proliferation 
Supplement, 20 ng/ml epidermal growth factor, 10 ng/ml 
basic fibroblast growth factor and 0.2% heparin 
(StemCell Technologies, Vancouver, BC, Canada) 
[19, 58, 59]. The cells isolated from tumor (GCSCs) and 
peritumoral (PCSCs) tissues generated neurospheres 
showing the typical properties of cancer stem-like cells 
as self-renewal, pluripotency, capability to establish a 
long-term expanding cultures as well as to generate tumor 
when inoculated into the right striatum of Scid/bg mice 
[19]. For propagation, GCSC and PCSC neurospheres 
were mechanically dissociated and cultured in the above 
described medium [19, 58, 59]. In all the experiments, 
GCSCs and PCSCs were used between passages 15 and 
20. Normal human astrocytes (SC-1800), used as positive 
control in the experiments evaluating H19 lncRNA/miR-
675-5p expression, were obtained from CliniSciences 
(Guidonia Montecelio, Italy) and cultured in astrocyte 
growth medium Kit (SC-1801, CliniSciences, Italy).
GCSC and PCSC proliferation analysis
Growth curves were plotted to compare the GCSC 
and PCSC proliferation rate. Cells were plated at a density 
of 8,000 cells/cm2 in culture medium. Every two days 
for one week, the two cell populations were collected, 
mechanically dissociated into single cell suspensions and 
counted with a hemocytometer.
Determination of cell viability by trypan blue dye 
exclusion test was carried out and all GCSC/PCSC pairs 
showed a viability never <90%.
RNA extraction and quantitative real-time PCR 
(qPCR)
Total RNA from GCSCs and PCSCs was extracted 
using the RNeasy Mini Kit (Qiagen, Chatsworth, CA, 
USA). cDNA was obtained by using SuperScript III 
Reverse Transcriptase (RT) (Invitrogen) and 1 µg of total 
RNA was primed with oligo-dT for cDNA synthesis. 
Quantitative PCR reactions were run in duplicate using 
IQTM SYBR Green QPCR Supermix (Bio-Rad) and 
fluorescent emission was recorded in real-time (Chromo 
4 Four-Color Real-Time PCR Detector, Bio-Rad). Gene 
expression profiling was completed using the comparative 
Ct method of relative quantification. Relative RNA 
quantities were normalized to GAPDH as endogenous 
control. To evaluate the expression of Nes (gene coding 
for Nestin protein), Msi1 (gene coding for Musashi-1 
protein), Sox2 (gene coding for SOX2 protein), c-Met 
(gene coding for c-Met protein), MAPK3 (gene coding 
for ERK1 protein), MAPK1 (gene coding for ERK2 
protein) and MAPK8 (gene coding for JNK protein), 
the following primer pairs were employed: MAPK1F1 
(5′-GATCACACAGGGTTCCTGAC-3′) and MAPK1R1 
(5′-CAGAATGCAGCCTACAGACC-3′); MAPK3F1 (5′-C 
TTCCTGACGGAGTATGTGG-3′) and MAPK3R1 (5′-CC 
GGTTAGAGAGCATCTCAG-3′); MAPK8F1 (5′-G 
TGTCTCCCTGGACTGTGAC-3′) and MAPK8R1 (5′-G 
AAGGAGAGGAATGGAGGAG-3′); MusashiF1 (5′-CA 
AAGTGTCTATCTGGGTGTGG-3′) and MusashiR1 (5′-T 
ATGATACAGGACGGGATGG-3′); Sox2F1 (5′-CCCTG 
TGGTTACTCTTCCT-3′) and Sox2R1 (5′-GTAGTGC 
TGGGACATGTGAAGT-3′); c-MetF1 (5′-TCCAAAT 
ATTGCCGTTTCATA-3′) and c-MetR1 (5′-CTATTGA 
TGCGTTCATGCTCT-3′); NestinF1 (5′-TTGCAGATG 
AGGAAGAAAGTG-3′) and NestinR1 (5′-CACAGAA 
TCAGACTCCAGGAA-3′). Total RNA for H19 and miR-
675-5p was isolated by TRIZOL reagent (Thermo Fisher 
Scientific), following manufacturer’s instructions. For 
H19 RNA measurement, 0.5 μg of total RNA isolated 
from samples (pre-treated with DNase I, New England 
Biolabs) were used to generate cDNA by the SensiFAST 
cDNA Synthesis Kit (Bioline, London, UK), according 
to the manufacturer’s instructions. For miR-675-5p 
measurement, 10 ng of total RNA were used to generate 
cDNA by TaqMan MicroRNA Reverse Transcription Kit 
(Applied Biosystems-Life Technologies), according to 
the manufacturer’s instructions. Quantitative PCRs were 
conducted on an StepOnePlus Real-Time PCR System 
(Applied Biosystems-Life Technologies) using TaqMan 
Universal PCR Master Mix and the specific TaqMan® 
Assays (probe and primer sets) (Applied Biosystems-Life 
Technologies). The small endogenous nuclear TBP and 
RNA U6 (RNU6B) were used as controls for normalization 
of H19 lncRNA and miR-675-5p, respectively. The 
relative amount of each substrate was calculated by the 
2−ΔΔCT method [60], and all results were expressed as 
compared to H19 lncRNA or miR-675-5p expression 
found in normal human astrocytes [61] set as = 1. 
All the primers were supplied by Applied Biosystems: 
RNU6B, ID 001093; TBP, ID Hs99999910_m1; H19, ID 
Hs00262142_g1; miR-675-5p, ID 002005.2.4.
Western blot analysis
GCSCs and PCSCs were lysed in cell lysis buffer 
(150 mM NaCl, 1% Nonidet P-40, 0.5% Triton X-100, 
0.5 mM EDTA, 0.1% SDS, 50 mM Tris-HCl, pH 7.6) 
containing a protease and phosphatase inhibitor cocktail 
(Sigma-Aldrich, St. Louis, MO, USA) supplemented 
with 17.4 μg/ml PMSF (Sigma-Aldrich). Proteins 
were quantified by Bradford Protein Assay (Bio-Rad 
Laboratories, Inc., Hercules, CA, USA). Twenty-five µg 
of total proteins were fractioned by 8–10% SDS-PAGE, 
transferred electrophoretically to a PVDF membrane 
(Immobilon-P Transfer Membrane, Millipore, Bedford, 
MA, USA) and immunoblotted with primary anti-Nestin 
(Clone 10C2, diluted 1:1000, Millipore), anti-Musashi-1 
(clone 282613, diluted 1:500, R&D Systems, Inc.), anti-
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SOX2 (Clone 245610, diluted 1:500, R&D Systems), anti-
c-Met (C-12, diluted 1:500, Santa Cruz Biotechnology), 
anti-phospho-Met (Tyr1234/1235) and anti-phospho-Met 
(Tyr 1349) (diluted 1:1000, Cell Signaling Technology), 
anti-phospho-pERK1/2 (Clone D13.14.4E, diluted 1:1000, 
Cell Signaling Technology), anti-pJNK (Clone G-7, 
diluted 1:500, Santa Cruz Biotechnology).
Membranes were then incubated with HRP-
conjugated secondary antibodies (diluted 1:160000, Sigma-
Aldrich). Detection of the bound antibody by enhanced 
chemiluminescence was performed using Immun-Star™ 
WesternC™ Chemiluminescence Kit (Bio-Rad Laboratories 
Inc, Hercules, CA, USA), according to the manufacturer’s 
instructions. Membranes were reprobed with an anti-β-
actin monoclonal antibody (clone AC15, diluted 1:5000, 
Sigma-Aldrich) as an internal control for protein loading. 
The signals were quantitated by densitometry (Chemi Doc 
Documentation System/Quantity One quantitation software, 
Bio-Rad). Densitometric units of the protein of interest were 
normalized with respect to total β-actin protein expression.
Immunocytochemical analysis
GCSCs and PCSCs were fixed in 4% 
paraformaldehyde, cryoprotected in 30% sucrose, snap-
frozen in liquid nitrogen and stored at –80° C until use. 
Immunocytochemistry was performed on frozen sections 
(10 μm) obtained from the neurospheres. Endogenous 
peroxidase activity was inhibited by incubation in 0.3% 
hydrogen peroxide and nonspecific reaction was blocked 
with Super Block, (Super Block, UCS Diagnostic S.r.l., 
Morlupo, Italy). The sections were then incubated 
overnight at 4° C with one of the following antibodies: 
anti-Nestin (clone 10C2, diluted 1:200, Millipore, 
Darmstadt, Germany), anti-Musashi-1 (Clone 282613, 
diluted 1:50, R&D Systems, Inc., Minneapolis, MN, 
USA), anti-SOX2 (Clone 245610, diluted 1:200, R&D 
Systems), anti-c-Met (C-12, diluted 1:300, Santa Cruz 
Biotechnology, Santa Cruz, CA, USA), anti-phospho-
ERK1/2 (Clone E10, diluted 1:250, Cell Signaling 
Technology, Beverly, MA, USA) and anti-pJNK (Clone 
G-7, diluted 1:50, Santa Cruz Biotechnology) which 
recognize the JNK1, JNK2, and JNK3 isoforms. Next, 
the sections were incubated at room temperature with 
HRP/Fab polymer conjugate (SuperPicTure Polymer 
DetectionKit, Thermo Fisher Scientific Inc. Waltham, 
MA, USA). A peroxidase DAB substrate kit (Vector 
Laboratories Inc., Burlingame, CA, USA) was used to 
visualize the immunostaining and Mayer’s hematoxylin 
was used to lightly counterstain nuclei. Negative controls 
were performed by omitting the primary antibodies.
Ultrastructural analysis
GCSCs and PCSCs were fixed in 2.5% glutaraldehyde 
in PBS (pH 7.4) and processed for transmission electron 
microscopy (TEM), following routine procedures [62]. 
Briefly, cells were post-fixed with 1.33% osmium tetroxide, 
dehydrated in graded alcohols, and then embedded in Epon 
812 resin (Fisher Chemical Co., Dallas, TX, USA). The 
resin was allowed to polymerize in a dry oven at 60° C, and 
specimens were cut on a Reichert ultra-microtome, stained 
with uranyl acetate and lead citrate, and observed under a 
Philips Morgagni 268D transmission electron microscope.
Statistical analysis
Statistical analysis was performed using the 
GraphPad Prisma software (GraphPad Software, San 
Diego, CA, USA). Data derived from at least two 
experiments (run in triplicates) were reported as mean 
value ± SD or SE. The comparison between GCSC 
and PCSC mRNA level was performed by t test pooled 
variance. As for the protein expression analysis, H19 
lncRNA and miR-675-5p as well as growth curves, the 
comparison between GCSCs and PCSCs was carried 
out by unpaired two-tailed Student t-test. An alpha level 
of less than 0.05 (p < 0.05) was considered statistically 
significant.
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